UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

AstraZeneca PLC
(Exact name of registrant as specified in its charter)

 

England and Wales
(State or other jurisdiction of incorporation or
organization)		 Not Applicable
(I.R.S. Employer
Identification No.)
   
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, United Kingdom
(Address of principal executive offices)		 CB2 0AA
(Zip Code)

 

AstraZeneca Finance LLC

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation or
organization)		 86-3730535
(I.R.S. Employer
Identification No.)
   

1209 Orange Street

Wilmington, Delaware

United States of America
(Address of principal executive offices)

 19801
(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered

 

Name of each exchange on which
each class is to be registered

4.875% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto)   The Nasdaq Stock Market LLC
4.900% Notes due 2030 (and the guarantee of AstraZeneca PLC related thereto)   The Nasdaq Stock Market LLC
4.875% Notes due 2033 (and the guarantee of AstraZeneca PLC related thereto)   The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: Not applicable.

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

 

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

AstraZeneca PLC (“AstraZeneca”) and AstraZeneca Finance LLC (“AstraZeneca Finance” and, together with AstraZeneca, the “Registrants”) filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), a prospectus supplement, dated February 28, 2023 (the “Prospectus Supplement”), and the accompanying prospectus, dated May 24, 2021 (the “Prospectus”). The Prospectus Supplement relates to the offering of $1,100,000,000 4.875% Notes due 2028, $650,000,000 4.900% Notes due 2030 and $500,000,000 4.875% Notes due 2033 issued by AstraZeneca Finance and fully and unconditionally guaranteed by AstraZeneca. The Prospectus forms a part of the Registrants’ Registration Statement on Form F-3 (File No. 333-256406) filed with the Commission on May 24, 2021. The Prospectus Supplement and the Prospectus are incorporated herein by reference to the extent set forth below.

 

Item 1. Description of Registrant’s Securities to Be Registered.

 

Reference is made to the information set forth under the headings “Description of Debt Securities and Guarantees” on pages 14 through 30 and “Certain UK and U.S. Federal Tax Considerations” on pages 35 through 43 of the Prospectus; and to the information set forth under the headings “Description of Notes” on pages S-12 through S-17 and “Taxation” on page S-18 of the Prospectus Supplement, which information is incorporated herein by reference.

 

Item 2. Exhibits.

 

Exhibit
No.		 Description
1.1 Registration Statement on Form F-3, including the Prospectus (incorporated herein by reference to the Registration Statement on Form F-3 filed with the Commission by AstraZeneca PLC and AstraZeneca Finance LLC on May 24, 2021 (File No. 333-256406)).
1.2 Prospectus Supplement (incorporated herein by reference to the prospectus filed with the Commission by AstraZeneca PLC and AstraZeneca Finance LLC on March 2, 2023 pursuant to Rule 424(b2)).
4.1 Indenture, dated as of May 28, 2021, among AstraZeneca Finance LLC, as issuer, AstraZeneca PLC, as guarantor, and The Bank of New York, as trustee (incorporated by reference to Exhibit 4.2 to the foreign private issuer report on Form 6-K filed with the Commission by AstraZeneca PLC on May 28, 2021).
4.2 Officers’ Certificate pursuant to Section 2.08 of the Indenture setting forth the terms of the AstraZeneca Finance securities, including forms of the global notes for the 4.875% Notes due 2028, the 4.900% Notes due 2030 and the 4.875% Notes due 2033 (incorporated by reference to Exhibit 4.1 to the foreign private issuer report on Form 6-K filed with the Commission by AstraZeneca PLC on March 3, 2023).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, each Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Dated: March 13, 2023 AstraZeneca PLC
  (Registrant)
   
  By: /s/ Jonathan Slade
    Name: Jonathan Slade
    Title: Group Treasurer

 

  AstraZeneca Finance LLC
  (Registrant)
   
  By: /s/ David E. White
    Name: David E. White
    Title: President, Treasurer and Director

 

 

 

AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more AstraZeneca Charts.